Table 2.
Inappropriate assessment prior to inpatient domperidone initiation in 2005 and 2012 (after Health Canada advisory).
| 2005 | 2012 | OR (95% CI) | |
|---|---|---|---|
| n = 207 | n = 113 | ||
| Safety/monitoring parameter | |||
| ECG not performed prior to initiation | 77 (37.2%) | 19 (16.8%) | 0.032 (0.006–0.156)∗ |
| QTc interval prolonged (>440 msec) | 170 (82.1%) | 76 (67.3%) | 0.025 (0.005–0.119)∗ |
| Ca2+ level unmeasured or abnormal | 117 (56.5%) | 32 (28.3%) | 0.311 (0.147–0.651)∗ |
| K+ level unmeasured or abnormal | 77 (37.2%) | 24 (21.2%) | 0.476 (0.204–1.109) |
| Mg2+ level unmeasured or abnormal | 42 (20.3%) | 29 (25.7%) | 1.623 (0.726–3.625) |
| LV function depressed (EF < 40%) | 99 (47.8%) | 11 (9.7%) | 0.220 (0.101–0.481)∗ |
| Concurrent use of other QT-prolonging drug(s) | 123 (59.4%) | 55 (48.7%) | 0.744 (0.375–1.476) |
Note: OR = odds ratio, CI = confidence interval, ECG = electrocardiogram, Ca2+ = serum calcium, K+ = serum potassium, Mg2+ = serum magnesium, LV = left ventricular, and EF = ejection fraction.
∗Significant difference in domperidone prescribing patterns between 2005 and 2012.